Hoffmann-la Roche Inc.

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Glycart Biotechnology Ag

Peter Bruenker

Christian Klein

Pablo Umana

Ekkehard Moessner

Ralf Hosse

Claudia Ferrara Koller

Sandra Grau-Richards

Maria Amann

Christina Claus

Viktor Levitski

Thomas U Hofer

Oliver Ast

Joerg Thomas Regula

Anne Freimoser-Grundschober

Christiane Neumann

Pablo Umaña

Guy Georges

Valeria G Nicolini

Harald Duerr

Inja Waldhauer

Stefan Seeber

Marina Bacac

Joerg Moelleken

Juergen Michael Schanzer

Huisheng Wang

Kathryn Elizabeth Packman

Tanja Fauti

Erhard Kopetzki

Wolfgang Schaefer

Ulrich Brinkmann

Kay-Gunnar Stubenrauch

Tilman Schlothauer

Sabine Imhof-Jung

Michael Molhoj

Jigar Patel

Frank Herting

Johannes Auer

Tina Weinzierl

Samuel Moser

Wei Xu

Sylvia Herter

Alexander Bujotzek

Christine Trumpfheller

Moritz Rapp

Maximiliane Koenig

Barbara Weiser

Valeria Runza

Joerg Zielonka

Tobias Suter

Huifeng Niu

Claudia Ferrara

Ningping Feng

Sherif Daouti

Marine Le Clech

Rebecca Croasdale

Jan Olaf Stracke

Eric Sullivan

Martina Geiger

Christiane Jaeger

Rebecca Croasdale-Wood

Christoph Lampert

Eva Carina Sum

Stephane Leclair

Valerla G Nicolini

Sandra Grau

Anne Freimoser-grundschober

Viktor Levitsky

Claudio Sustmann

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-FAP clone 212

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for OX40

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

T cell activating bispecific antigen binding molecules

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use

The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.

Antibody fab and Fc variants

The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer

Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer

The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.

Protease-activated T cell bispecific molecules

The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Antibodies specific for DR5 and methods of use

Growing community of inventors

Hittnau, Switzerland

Peter Bruenker